In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 17.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by June 20, 2022. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Request for Credit Survey

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Printable List of CME-Designated Sessions

Statement of Educational Need, Target Audience, and Learning Objectives

Liver cancer is a major health problem, the 4th leading cause of cancer-related deaths globally. By 2025 the incidence of liver cancer is estimated to reach 1 million individuals. There have been major advances in the understanding of the pathogenesis and treatment of the two main types of liver cancer: hepatocellular carcinoma and cholangiocarcinoma. Still, most patients do not present at a curative stage and outcomes are often less than optimal in at-risk populations.

In hepatocellular carcinoma (HCC), there are established proposals for molecular classification and immune classification of this disease, however, unlike in other malignancies these are yet to have impacted clinical practice. Some of these subclasses are linked with potential therapeutic effect but need assay development and validation.  In addition, the landscape of mutations and mutational signatures have been recently reported. Several basic studies have provided an understanding of the distinct pathogenesis of HCC regarding etiology, being now established specific information on the path from chronic inflammation due to HCV and HBV and development of HCC. More recently, it has been pointed out a unique immune-based pathogenesis associated to HCC development in patients with non-alcoholic steatohepatitis (NASH) associated to metabolic syndrome. Overall, the role tumor microenvironment, immune involvement and microbiome in the pathogenesis of the disease will be reviewed. Finally, optimal animal models recapitulating specific HCC subclasses or etiologies to explore the pathogenesis of this neoplasm will be reviewed.

From the therapeutic stand-point, several molecular therapies have been recently shown to provide clinical benefit in patients with advanced HCC beyond sorafenib, such as lenvatinib (in first line) and regorafenib, cabozantinib and ramucirumab (second line). Understanding the mechanism of action, specific benefits in subgroups of patients, and biomarkers predicting response are major issues that will be fully reviewed.  Similarly, proposed biomarkers of response/resistance to checkpoint inhibitors in HCC and rationale for the recent positive phase III study with atezolizumab+ bevacizumab vs sorafenib will be reviewed. The role of biomarkers, trial design, liquid biopsy and rationale for future combinations will also be explored.

In cholangiocarcinoma, major advances in the understanding of the landscape of mutations and principal drivers of the disease have been reported, particularly differentiating intrahepatic cholangiocarcinoma (iCCA) compared to extrahepatic cholangiocarcinoma (eCCA). In terms of management, two concepts of precision oncology have moved forward: First, the fact that 25% of iCCA present fusion drivers of FGFR2 led to the launch of proof-of-concept trials with positive signals of efficacy in phase II. Similarly, IDH mutations present in around 15% of iCCA were used to enrich phase III studies testing IDH inhibitors, and leading to positive phase III data in terms of PFS. Other advances in the management of iCCA such as new data in the adjuvant setting (capecitabine) will be reviewed.

Hepatoblastoma is the main liver tumor in children. Since it is a rare tumor, understanding the mechanism of oncogenesis in hepatoblastoma remains to be done. Recently several reports have described more precisely the genomic landscape of hepatoblastoma and the important question of the cell at the origin of the various tumors emerged. Several new therapeutic options have also emerged in pre-clinical models, results that could be used to design new treatments in children with tumor resistant to cisplastin.

Attendees are encouraged to join in the conversation, with basic scientists, physician-scientists, and industry professionals all united towards the common goal of improving research and management of this aggressive disease.

After participating in this CME activity, physicians should be able to:

  1. Interpret the molecular pathogenesis of HCC and iCCA, including role of tumor microenvironment, immune component and microbiome.
  2. Identify key drivers and pathways potentially actionable in these diseases.
  3. Distinguish the role of molecular and immune classes in HCC and iCCA.
  4. Explain the main experimental models to explore the pathogenesis of liver cancer.
  5. Translate molecular drivers in therapies for the clinic.
  6. Explain major advances in the molecular treatment of HCC and iCCA, and the key elements on trial design.
  7. Detect biomarkers predicting response of primary resistance to molecular therapies.
  8. Demonstrate the role of liquid biopsy in early detection, selection of patients for therapies and detection of resistant mechanisms.
  9. Evaluate at-risk populations and areas of unmet need in liver cancer research and care.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.

Planner and Speaker Financial Disclosure Index

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants which will be disclosed at the activity.

Questions about CME?

AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer FAQ’s

Please contact the Office of CME at (215) 440-9300 or [email protected].